Alignment Healthcare (NASDAQ:ALHC) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen lowered shares of Alignment Healthcare (NASDAQ:ALHC) from a buy rating to a hold rating in a report released on Saturday morning.

Other equities analysts have also issued research reports about the company. Weiss Ratings raised Alignment Healthcare from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. UBS Group restated a “neutral” rating on shares of Alignment Healthcare in a research report on Wednesday, July 8th. Barclays cut their price target on shares of Alignment Healthcare from $19.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 26th. Zacks Research lowered shares of Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Wolfe Research initiated coverage on shares of Alignment Healthcare in a report on Friday, April 17th. They set an “outperform” rating and a $24.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Alignment Healthcare currently has a consensus rating of “Moderate Buy” and an average target price of $24.30.

Alignment Healthcare Price Performance

ALHC opened at $14.85 on Friday. The company has a fifty day moving average price of $19.70 and a two-hundred day moving average price of $19.76. The firm has a market capitalization of $3.07 billion, a PE ratio of 78.16, a P/E/G ratio of 2.01 and a beta of 1.05. Alignment Healthcare has a 52 week low of $12.91 and a 52 week high of $25.12. The company has a debt-to-equity ratio of 1.56, a quick ratio of 1.58 and a current ratio of 1.58.

Alignment Healthcare (NASDAQ:ALHC) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.04. Alignment Healthcare had a return on equity of 22.28% and a net margin of 0.89%.The company had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter in the prior year, the business posted $0.07 EPS. The firm’s quarterly revenue was up 31.6% on a year-over-year basis. As a group, analysts anticipate that Alignment Healthcare will post 0.2 earnings per share for the current year.

Insider Activity

In other Alignment Healthcare news, President Dawn Christine Maroney sold 30,000 shares of the business’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $16.09, for a total value of $482,700.00. Following the completion of the transaction, the president directly owned 998,813 shares of the company’s stock, valued at approximately $16,070,901.17. The trade was a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joseph S. Konowiecki sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $24.00, for a total value of $600,000.00. Following the sale, the executive vice president directly owned 1,103,816 shares in the company, valued at approximately $26,491,584. This represents a 2.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 1,039,951 shares of company stock valued at $19,976,967. Company insiders own 5.20% of the company’s stock.

Institutional Trading of Alignment Healthcare

Hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada boosted its holdings in shares of Alignment Healthcare by 92.6% in the first quarter. Royal Bank of Canada now owns 92,379 shares of the company’s stock valued at $1,720,000 after buying an additional 44,413 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Alignment Healthcare by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,557 shares of the company’s stock valued at $1,109,000 after acquiring an additional 2,594 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Alignment Healthcare by 79.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 972,715 shares of the company’s stock valued at $18,112,000 after acquiring an additional 429,703 shares in the last quarter. Woodline Partners LP acquired a new position in Alignment Healthcare in the 1st quarter worth $2,142,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Alignment Healthcare by 16.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 307,655 shares of the company’s stock worth $5,729,000 after purchasing an additional 44,452 shares during the period. 86.19% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Q2 results exceeded expectations: Alignment reported adjusted earnings of $0.17 per share, above the $0.13 consensus estimate, while revenue of $1.34 billion surpassed estimates of $1.31 billion. Revenue increased 31.6% year over year, and net income more than doubled to $36.6 million as Medicare Advantage care costs improved. Alignment Healthcare Reports Second Quarter 2026 Results
• Positive Sentiment: Operating performance is improving: The company said it surpassed the high end of its guidance across key metrics, reflecting stronger membership growth, revenue, and profitability compared with the prior-year period. Alignment Healthcare Turns Profit
• Neutral Sentiment: Guidance remained broadly in line: Full-year 2026 revenue guidance was approximately $5.2 billion, and third-quarter revenue guidance was approximately $1.3 billion, generally matching analyst expectations. The lack of a material forecast increase may have limited the earnings-driven upside.
• Negative Sentiment: Several law firms announced investigations: Frank R. Cruz, Block & Leviton, Kaplan Fox, Lowey Dannenberg, and Pomerantz publicized inquiries into possible securities-law violations and alleged financial manipulation. The investigations follow an earlier sharp drop in ALHC shares and could create legal costs, reputational damage, and uncertainty regarding the company’s disclosures. The allegations have not been proven. Securities Fraud Investigation Into Alignment Healthcare

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.